Alberto-Culver Founder Leonard Lavin Joins Histogen Board of Directors

Share Article

Histogen, Inc., a regenerative medicine company developing solutions based on the products of newborn fibroblasts, today announced that Leonard Lavin, founder and chairman emeritus of the Alberto-Culver Company, has joined Histogen's Board of Directors.

Histogen, Inc., a regenerative medicine company developing solutions based on the products of newborn fibroblasts, today announced that Leonard Lavin, founder and chairman emeritus of the Alberto-Culver Company, has joined Histogen's Board of Directors.

In addition to his distinguished career with Alberto-Culver, a Fortune 1000 consumer products company, Leonard Lavin's experience and interests cross various industries. In 1946, Lavin joined Halgar, Inc., a company specializing in toiletry products, where he was instrumental in building the company into one of the leaders in its field. Lavin also formed the Excello Sales Agency, where he gained exclusive advertising and sales rights for Stopette spray deodorant, which went on to become the number one product of its kind.

Leonard Lavin and his wife Bernice bought Alberto-Culver Company in 1955 for $400,000, and turned it into a multi-billion dollar company. By positioning his products and making innovative use of television advertisements, Lavin has supplied the world with some of the most well known hair, skin and personal care products.

"Mr. Lavin's extraordinary business acumen will be invaluable as Histogen enters a tremendous stage of growth in 2008," said Gail K. Naughton Ph.D., Histogen founder and Chairman of the Board. "Leonard has proven himself to be a marketing genius, and having someone with his expertise join the board truly validates Histogen's distinctive business model."

Histogen, launched in 2007, seeks to redefine regenerative medicine by developing a series of high value products without the use of embryonic stem cells or animal products. The company's business plan benefits from the lessons learned at Advanced Tissue Sciences, and focuses on near, mid and long term products that are either self-pay or reimbursable.

"I am excited to be a new director on Histogen's board, and look forward to contributing to the company's success," said Lavin. "The field of regenerative medicine offers many potential therapeutic and cosmetic benefits, and Histogen's unique technology positions the company to be a global leader in the field."

Through Histogen's proprietary bioreactors that mimic the embryonic environment, newborn fibroblasts are encouraged to naturally produce the vital proteins and growth factors from which the company has developed its rich product portfolio. For more information, please visit http://www.histogeninc.com.

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Eileen Naughton
Histogen
619-318-7821
Email >
Visit website